The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Intercept Pharmaceuticals Inc

Nasdaq: ICPT
Last

(U.S.) $158.20

Today's change+5.04 +3.29%
Updated July 22 4:00 PM EDT. Delayed by at least 15 minutes.
 

Intercept Pharmaceuticals Inc

Nasdaq: ICPT
Last

(U.S.) $158.20

Today's change+5.04 +3.29%
Updated July 22 4:00 PM EDT. Delayed by at least 15 minutes.

Intercept Pharmaceuticals Inc Hits New 20-day High

Intercept Pharmaceuticals Inc closed up sharply Friday, rallying (U.S.)$5.04 or 3.29% to (U.S.)$158.20 and setting a new 20-day high. Over the last five days, shares have gained 6.37% and 5.93% year to date. Shares have underperformed the S&P 500 by 44.14% during the last year.

Key company metrics

  • Open(U.S.) $152.33
  • Previous close(U.S.) $153.16
  • High(U.S.) $159.05
  • Low(U.S.) $151.20
  • Bid / Ask(U.S.) $138.11 / (U.S.) $173.33
  • YTD % change+5.93%
  • Volume320,210
  • Average volume (10-day)354,618
  • Average volume (1-month)543,835
  • Average volume (3-month)604,794
  • 52-week range(U.S.) $89.76 to (U.S.) $285.00
  • Beta-2.41
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$12.89
Updated July 22 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-17,614.71%

Intercept Pharmaceuticals Inc has a net profit margin of -17,614.71%. Besides being negative, it is also below the industry average and implies that this company is not effective at turning revenues into bottom line profit.
Company Books

S&P TSX0.24%Sector:HealthcareIndustry:Biotechnology

Latest Company News

  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2016Q4/2015Q3/2015Q2/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201603/31/2016Dec 31, 201512/31/2015Sep 30, 201509/30/2015Jun 30, 201506/30/2015
Revenue0000
Total other revenue--------
Total revenue0000
Gross profit--------
Total cost of revenue--------
Total operating expense128895249
Selling / general / administrative90452521
Research & development37442728
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-127-89-52-49
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-127-88-51-48
Income after tax-127-88-51-48
Income tax, total--------
Net income-127-88-51-48
Total adjustments to net income--------
Net income before extra. items-127-88-51-48
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-127-88-51-48
Inc. avail. to common incl. extra. items-127-88-51-48
Diluted net income-127-88-51-48
Dilution adjustment--------
Diluted weighted average shares24242424
Diluted EPS excluding extraordinary itemsvalue per share-5.17-3.62-2.10-1.99
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-5.17-3.62-2.10-1.99